Blueprint Medicines Corporation
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Blueprint Medicines Corporation, now operating as a Sanofi company, is a biopharmaceutical firm focused on developing precision therapies for genomically defined cancers and rare immunological conditions across the globe. The company offers AYVAKIT®/AYVAKYT® (avapritinib), a kinase inhibitor approved for various indications including adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, advanced systemic mastocytosis (AdvSM), and indolent systemic mastocytosis (ISM) with moderate to severe symptoms. Its portfolio also historically included GAVRETO® (pralsetinib), an oral precision therapy targeting RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer; however, the U.S. rights for GAVRETO were transitioned to Rigel Pharmaceuticals in February 2024. Within its robust pipeline, Blueprint Medicines is progressing elenestinib (BLU-263), a next-generation KIT D816V inhibitor currently in a registration-enabling Phase 3 trial for indolent systemic mastocytosis. Another significant candidate is BLU-808, a highly selective oral wild-type KIT inhibitor undergoing Phase 2 evaluation for chronic inducible urticaria and chronic spontaneous urticaria, with broader potential across immunological diseases. Additionally, fidrisertib (formerly BLU-782), an ALK2 inhibitor, is licensed exclusively worldwide to Clementia Pharmaceuticals, a subsidiary of Ipsen, for fibrodysplasia ossificans progressiva. The company further expanded its scientific platform to include targeted protein degradation through a collaboration with VantAI, which was recently amended in May 2025 to advance novel therapies. Blueprint Medicines was initially incorporated in October 2008 and adopted the name Blueprint Medicines Corporation in June 2011. The enterprise maintains its headquarters in Cambridge, Massachusetts. In a significant strategic move, Sanofi entered into an agreement to acquire Blueprint Medicines Corporation for up to $9.5 billion in June 2025, thereby integrating its precision medicine capabilities into Sanofi's rare immunology and oncology portfolios.
Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC)
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders
BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders
Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript
Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates